Tema ETF Trust NPORT-P Tema Oncology ETF (Nov 2023 report)

Tema ETF Trust
Tema Oncology ETF
Schedule of Investments
November 30, 2023 (Unaudited)
Investments	Number of Shares		Value
COMMON STOCKS - 96.1%
Biotechnology - 58.6%
Agios Pharmaceuticals, Inc.*		9,438	$	209,807
Arcellx, Inc.*		3,708		194,781
Arcus Biosciences, Inc.*		11,141		167,783
Argenx SE - ADR*^		1,206		543,436
BeiGene Ltd. - ADR*^		2,442		456,507
Blueprint Medicines Corp.*		565		39,347
Celldex Therapeutics, Inc.*		11,560		349,228
Cogent Biosciences, Inc.*		12,936		99,219
CRISPR Therapeutics AG - ADR*^		7,266		484,860
Cullinan Oncology, Inc.*		15,906		130,270
CureVac N.V. - ADR*^		14,787		79,850
Day One Biopharmaceuticals, Inc.*		12,540		145,213
Deciphera Pharmaceuticals, Inc.*		18,085		228,052
Exact Sciences Corp.*		4,356		278,784
Exelixis, Inc.*		17,959		391,686
Fusion Pharmaceuticals, Inc. - ADR*^		54,978		304,578
Genmab A/S - ADR*^		11,946		377,613
Gilead Sciences, Inc.		6,608		506,173
Immunocore Holdings plc - ADR*^		3,828		201,850
ImmunoGen, Inc.*		17,626		517,323
Incyte Corp.*		7,524		408,854
Intellia Therapeutics, Inc.*		16,368		484,984
Legend Biotech Corp. - ADR*^		4,700		285,854
Mereo Biopharma Group plc - ADR*^		192,329		401,968
Merus N.V. - ADR*^		7,194		177,980
Mirati Therapeutics, Inc.*		2,392		135,746
Moderna, Inc.*		3,252		252,680
MorphoSys AG*^		2,332		61,835
Regeneron Pharmaceuticals, Inc.*		990		815,572
Relay Therapeutics, Inc.*		22,110		174,890
Revolution Medicines, Inc.*		9,250		215,802
SpringWorks Therapeutics, Inc.		2,789		84,758
Zentalis Pharmaceuticals, Inc.*		5,235		58,894
				9,266,177
Health Care Equipment & Supplies - 3.8%
Lantheus Holdings, Inc.*		3,564		255,254
Siemens Healthineers AG^ (a)		6,090		350,935
				606,189
Health Care Providers & Services - 4.0%
Guardant Health, Inc.*		15,856		399,096
Option Care Health, Inc.*		7,659		227,855
				626,951
Health Care Technology - 2.3%
Schrodinger, Inc.*		11,635		361,732
Life Sciences Tools & Services - 4.7%
10X Genomics, Inc., Class A *		6,270		272,870
Illumina, Inc.*		4,623		471,315
				744,185
Pharmaceuticals - 22.7%
Arvinas, Inc.*		6,864		150,802
AstraZeneca plc^		4,620		590,601
Bristol-Myers Squibb Co.		7,463		368,523
Chugai Pharmaceutical Co., Ltd.^		13,926		490,125
Daiichi Sankyo Co., Ltd.^		21,912		591,178
Merck & Co., Inc.		7,390		757,327
Novartis AG^		6,488		630,648
				3,579,204
TOTAL COMMON STOCKS (Cost $14,794,342)				15,184,438
SHORT-TERM INVESTMENTS - 1.3%
Money Market Fund
First American Treausry Obligations Fund - Class X, 5.277% (b)		211,740		211,740
TOTAL SHORT-TERM INVESTMENTS (Cost $211,740)				211,740
TOTAL INVESTMENTS (Cost $15,006,082)  - 97.4%				15,396,178
OTHER ASSETS LESS LIABILITIES - 2.6%				408,828
NET ASSETS - 100.0%			$	15,805,006

* Non-income producing security.

^ Foreign security.

(a) Securities purchased pursuant to Rule 144A of the Securities Act of 1933, as amended, and may be sold only to dealers in that program or other “qualified institutional buyers.” These securities have been deemed to be liquid by the Fund’s adviser under the supervision of the Board of Trustees. As of November 30, 2023, the value of these investments was $350,935 or 2.2% of total net assets.

(b) 7-day net yield.

ADR - American Depositary Receipt

plc- Public Limited Company

The Global Industry Classification Standard (GICS^®) was developed by and/or is the exclusive property of MSCI, Inc. and Standard & Poor Financial Services LLC (“S&P”). GICS is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services.

Tema Oncology ETF
November 30, 2023 (Unaudited)
ALLOCATION BY SECTOR
Sector	Percentage of Total Net Assets
Health Care	96.1%
Money Market Fund and Other Assets and Liabilities	3.9%
Total	100.0%

ALLOCATION BY COUNTRY
Country	Percentage of Total Net Assets
United States	59.3%
United Kingdom	7.6%
Switzerland	7.1%
Japan	6.8%
Netherlands	5.1%
Cayman Islands	4.7%
Germany	2.6%
Denmark	2.4%
Canada	1.9%
Other(1)	2.5%
Total	100.0%
(1) Includes cash and net other assets (liabilities).

Tema ETF Trust

Tema Oncology ETF

Notes to Quarterly Schedule of Investments

November 30, 2023 (Unaudited)

Investment Valuation

The Fund discloses the fair value of their investments in a hierarchy that distinguishes between: (1) market participant assumptions developed based on market data obtained from sources independent of the Fund's (observable inputs) and (2) the Fund's’ own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:

• Level 1 — Quoted prices in active markets for identical assets that the Fund's have the ability to access.

• Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).

• Level 3 — Significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund's investments as of November 30, 2023:

Tema Oncology ETF	Level 1		Level 2		Level 3		Total
Investments
Common Stocks *	$	15,184,438	$	-	$	-	$	15,184,438
Money Market Fund		211,740		-		-		211,740
Total Investments	$	15,396,178	$	-	$	-	$	15,396,178
* See Schedule of Investments for segregation by industry.